HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $41
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Edward White maintains a 'Buy' rating on TG Therapeutics (NASDAQ:TGTX) and raises the price target from $34 to $41.
August 04, 2023 | 9:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The 'Buy' rating maintained by HC Wainwright & Co. and the raised price target could potentially lead to an increase in TG Therapeutics' stock price.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The maintained 'Buy' rating and increased price target indicate a positive outlook for TG Therapeutics, which could lead to increased investor interest and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100